| nr |
titel |
auteur |
tijdschrift |
jaar |
jaarg. |
afl. |
pagina('s) |
type |
| 1 |
A-174 Acitretin as a noninferior retinoid alternative to bexarotene in the management of mycosis fungoides
|
Johnson, B.
|
|
|
211 |
S2 |
p.
|
artikel
|
| 2 |
A-297 Acneiform Case of Mogamulizumab-associated rash
|
Booken, N.
|
|
|
211 |
S2 |
p.
|
artikel
|
| 3 |
A-223 AI-assisted Evaluation of CD4/CD8-Ratio in Mycosis fungoides
|
Zhelyazkov, G.
|
|
|
211 |
S2 |
p.
|
artikel
|
| 4 |
A-289 Allogeneic stem cell transplantation in advanced cutaneous T cell lymphoma offers the potential for cure
|
Hatzakis, A.
|
|
|
211 |
S2 |
p.
|
artikel
|
| 5 |
A-193 A Prospective, US-based Study Assessing Mogamulizumab-Associated Rash in Patients Diagnosed with Mycosis Fungoides or Sézary Syndrome and Treated with Standard of Care Mogamulizumab
|
Querfeld, C.
|
|
|
211 |
S2 |
p.
|
artikel
|
| 6 |
A-105 A Retrospective comparison between Home and In-office NB-UVB Efficacy for patients with Mycosis Fungoides
|
Garfinkel, V.
|
|
|
211 |
S2 |
p.
|
artikel
|
| 7 |
A-278 Assessing Inter-Rater Reliability in Mycosis Fungoides: Impact of Clinician Experience on Skin Involvement Assessments
|
Kersten, J.
|
|
|
211 |
S2 |
p.
|
artikel
|
| 8 |
A-172 Atypical Epidermotropic Infiltrate with NK cell immunophenotype Following Systemic Therapy for Atopic Dermatitis - A Case Report
|
Moritz, R.K.
|
|
|
211 |
S2 |
p.
|
artikel
|
| 9 |
A-164 B cells are associated with aggressive Cases of Cutaneous T cell Lymphoma and a distinct spatio-temporal composition of the tumor microenviroenment
|
Oganesian, S.
|
|
|
211 |
S2 |
p.
|
artikel
|
| 10 |
A-139 B2 involvement as a surrogate marker for a rapid and sustained response to treatment with mogamulizumab in mycosis fungoides and Sézary syndrome
|
Stadler, R.
|
|
|
211 |
S2 |
p.
|
artikel
|
| 11 |
A-245 Brentuximab vedotin as second-line treatment for primary cutaneous CD8+ aggressive epidermotropic T-cell lymphoma
|
Calvão, J.
|
|
|
211 |
S2 |
p.
|
artikel
|
| 12 |
A-196 Can histopathology contribute to a better definition of patches and plaques in early stage mycosis fungoides?
|
Kersten, J.
|
|
|
211 |
S2 |
p.
|
artikel
|
| 13 |
A-206 4 cases of pediatrics mycosis fungoides revealed by recalcitrant psoriatic palmoplantar keratoderma
|
Grandjacquot, S.
|
|
|
211 |
S2 |
p.
|
artikel
|
| 14 |
A-119 CD30 expression on mast cells in cutaneous mastocytosis as a potential therapeutic target
|
Mitteldorf, C.
|
|
|
211 |
S2 |
p.
|
artikel
|
| 15 |
A-234 CD30+ Primary Cutaneous Follicle Center Lymphoma: an atypical immunohistochemical profile
|
Farizano, L.A.
|
|
|
211 |
S2 |
p.
|
artikel
|
| 16 |
A-135 Challenges in differentiating among the primary cutaneous lymphoproliferative diseases with gamma-delta phenotype - a case report
|
Ali, S.
|
|
|
211 |
S2 |
p.
|
artikel
|
| 17 |
A-159 Characteristics and Outcomes for Granulomatous Mycosis Fungoides in 80 Patients
|
Arkatkar, S.
|
|
|
211 |
S2 |
p.
|
artikel
|
| 18 |
A-148 Chlormethine Gel Effectiveness as second-line Treatment in Mycosis fungoides: a single-centre Retrospective Study
|
Zengarini, C.
|
|
|
211 |
S2 |
p.
|
artikel
|
| 19 |
A-163 Chlormethine Gel Shows Efficacy as Monotherapy in Stages IA-IIB Mycosis Fungoides
|
Browne, R.
|
|
|
211 |
S2 |
p.
|
artikel
|
| 20 |
A-268 Chlormethine Treatment Effectively Targets the Tumor Micro-Environment in Early-stage Mycosis Fungoides Patients
|
Wind, S.
|
|
|
211 |
S2 |
p.
|
artikel
|
| 21 |
A-187 Circadian Rhythms in Hematological Malignancies
|
Motiei, M.
|
|
|
211 |
S2 |
p.
|
artikel
|
| 22 |
A-294 Clinical diversity and treatment approaches to blastic plasmacytoid dendritic cell neoplasm: a retrospectivemulticentre study [PUBLISHED ARTICLE]
|
Brüggen, M.-C.
|
|
|
211 |
S2 |
p.
|
artikel
|
| 23 |
A-273 Clinician Practice Patterns and Recommendations for Bone Marrow Biopsy in Cutaneous T-Cell Lymphoma
|
Slavinsky, V.
|
|
|
211 |
S2 |
p.
|
artikel
|
| 24 |
A-226 Clonal evolution, antigens, and triggers in Cutaneous T Cell Lymphoma pathogenesis
|
Gumina, M.
|
|
|
211 |
S2 |
p.
|
artikel
|
| 25 |
A-254 Comparing Responses to Romidepsin Monotherapy and the Sequential Treatment of Romidepsin Followed by Mogamulizumab for Advanced Cutaneous T-cell Lymphoma
|
Gordon, E.
|
|
|
211 |
S2 |
p.
|
artikel
|
| 26 |
A-188 Correlation of skin barrier function, bacterial colonization, and inflammation in Mycosis Fungoides and Sézary Syndrome
|
Beljaards, E.S.M.
|
|
|
211 |
S2 |
p.
|
artikel
|
| 27 |
A-161 CTPS1 is a novel therapeutic target in cutaneous T cell lymphoma
|
Beer, P.
|
|
|
211 |
S2 |
p.
|
artikel
|
| 28 |
A-156 Current State and Therapeutic Potential of CCR4 Therapies in Cutaneous T-Cell Lymphomas
|
Zengarini, C.
|
|
|
211 |
S2 |
p.
|
artikel
|
| 29 |
A-142 Cutaneous T-cell lymphoma in pregnancy: disease activity and outcomes
|
Lohray, R.
|
|
|
211 |
S2 |
p.
|
artikel
|
| 30 |
A-116 Cytokine-pathway blockers worsen mycosis fungoides masquerading as psoriasis
|
Blanchard, G.
|
|
|
211 |
S2 |
p.
|
artikel
|
| 31 |
A-157 Cytokines in CTCL: Current Insights and Therapeutic Targets
|
Pileri, A.
|
|
|
211 |
S2 |
p.
|
artikel
|
| 32 |
A-192 Deciphering reliable mycosis fungoides-specific diagnostic classifiers and personalized therapeutic regimens through spatial single-cell type proteomics in tissues
|
Zheng, X.
|
|
|
211 |
S2 |
p.
|
artikel
|
| 33 |
A-114 Deep learning-based classification of early-stage mycosis fungoides and benign inflammatory dermatoses on hematoxylin and eosinstained whole-slide images: a retrospective, proof-of-concept study
|
Doeleman, T.
|
|
|
211 |
S2 |
p.
|
artikel
|
| 34 |
A-158 Dermatoscopy in CTCL: Evaluating Diagnostic Potential and Patterns
|
Zengarini, C.
|
|
|
211 |
S2 |
p.
|
artikel
|
| 35 |
A-152 Dissecting the role of CXCR4 in mycosis fungoides: from gene editing to therapeutic molecule
|
Moyal, L.
|
|
|
211 |
S2 |
p.
|
artikel
|
| 36 |
A-165 Dissecting the role of macrophages in different spatial locations in Mycosis fungoides
|
Fischer, B.
|
|
|
211 |
S2 |
p.
|
artikel
|
| 37 |
A-243 Dissecting the Tumor Microenvironment in Mycosis Fungoides: Aberrant T Cell Subsets and Immune Profiling
|
Vetsika, E.-K.
|
|
|
211 |
S2 |
p.
|
artikel
|
| 38 |
A-108 Drug-induced mimics of Mycosis Fungoides: Two case reports and a systemic literature review
|
Garfinkel, V.
|
|
|
211 |
S2 |
p.
|
artikel
|
| 39 |
A-167 Durable disease control with low-dose total skin electron beam therapy combined with maintenance treatment for patients with erythrodermic mycosis fungoides and Sézary syndrome
|
Elsayad, K.
|
|
|
211 |
S2 |
p.
|
artikel
|
| 40 |
A-141 Dysbiosis of the skin microbiome in patients with Mycosis fungoides
|
Belfrage, E.
|
|
|
211 |
S2 |
p.
|
artikel
|
| 41 |
A-249 Effectiveness and safety of chlormethine gel in the treatment of mycosis fungoides affecting “sensitive” areas: A real-world experience from two tertiary referral centres
|
Violetti, S. Alberti
|
|
|
211 |
S2 |
p.
|
artikel
|
| 42 |
A-136 Effects of Mogamulizumab on CD39, CD73 and CD38 ectonucleotidases expression in T-cells of Sézary syndrome patients
|
Roccuzzo, G.
|
|
|
211 |
S2 |
p.
|
artikel
|
| 43 |
A-296 Efficacy and safety of pembrolizumab and radiotherapy in relapsed/refractory cutaneous T cell lymphoma: results of the PORT trial
|
Morris, S.
|
|
|
211 |
S2 |
p.
|
artikel
|
| 44 |
A-213 αEβ7 Integrin (CD103) expression in both early and advanced stage of Cutaneous T cell Lymphoma's (CTCL)
|
Merkus, V.A.
|
|
|
211 |
S2 |
p.
|
artikel
|
| 45 |
A-113 Eleven years RealWorld Data: Epidemiology and care reality of patients with CTCL in Germany - Retrospective statuory health insu rance (SHI) claims data analyses
|
Dobos, G.
|
|
|
211 |
S2 |
p.
|
artikel
|
| 46 |
A-264 Enhanced Phototherapeutic Efficacy Through Microbial Modulation in Cutaneous T-Cell Lymphoma delays tumour growth and increases survival in the murine EL4 model
|
Dey, S.
|
|
|
211 |
S2 |
p.
|
artikel
|
| 47 |
A-293 Erythrodermic Folliculotropic Mycosis Fungoïdes successfully treated with Bexaroten plus nbUVB and chlormethine gel
|
Bernard, P.
|
|
|
211 |
S2 |
p.
|
artikel
|
| 48 |
A-169 Establishment of a special electron beam therapy system for the treatment of mycosis fungoides
|
Lee, M.
|
|
|
211 |
S2 |
p.
|
artikel
|
| 49 |
A-224 Evaluating the Impact of Phototherapy on Cardiovascular Risk in Cutaneous T-Cell Lymphoma: A Retrospective Analysis
|
Niknejad, K.
|
|
|
211 |
S2 |
p.
|
artikel
|
| 50 |
A-214 Evaluation of Sézary cell marker expression and cell death behavior upon in vitro treatment by flow cytometry in Sézary Syndrome patients
|
Melchers, S.
|
|
|
211 |
S2 |
p.
|
artikel
|
| 51 |
A-144 Exploring the association of CD30+ Lymphoproliferative Disorders and Inflammatory Conditions in a Dutch Cohort
|
Ottevanger, R.
|
|
|
211 |
S2 |
p.
|
artikel
|
| 52 |
A-260 Extracorporeal photopheresis leads to short-term, but not long-term changes in peripheral blood count analysis of patients with cutaneous T-cell lymphoma
|
Graier, T.
|
|
|
211 |
S2 |
p.
|
artikel
|
| 53 |
A-246 Extranodal natural killer/T-cell lymphoma, nasal-type, with extranasal cutaneous presentation - report of 3 cases
|
Calvão, J.
|
|
|
211 |
S2 |
p.
|
artikel
|
| 54 |
A-222 Flow cytometry of skin biopsies in CTCL patients during Mogamulizumab treatment
|
de Bie, F.J.
|
|
|
211 |
S2 |
p.
|
artikel
|
| 55 |
A-149 For something completely different: granuloma annulare-like histiocytosis as skin specific manifestation of ETV6::SYK rearranged myeloid neoplasm with eosinophilia
|
Croci, G.A.
|
|
|
211 |
S2 |
p.
|
artikel
|
| 56 |
A-253 Functional characterization of SAMDH1 in Cutaneous T-cell lymphoma
|
Song, D.
|
|
|
211 |
S2 |
p.
|
artikel
|
| 57 |
A-166 Health-related quality of life in primary cutaneous B-cell lymphoma following local radiotherapy
|
Heger, A.
|
|
|
211 |
S2 |
p.
|
artikel
|
| 58 |
A-229 Identification of clones by TCR Vβ repertoire analysis supports diagnosis of leukemic cutaneous T-cell lymphoma
|
Woltsche, J.
|
|
|
211 |
S2 |
p.
|
artikel
|
| 59 |
A-216 Identification of subgroups of early-stage mycosis fungoides patients with increased itch and impaired quality of life
|
Nenonen, J.
|
|
|
211 |
S2 |
p.
|
artikel
|
| 60 |
A-162 Identifying Patients With Poor Outcomes in Mycosis Fungoides & Sezary syndrome For Improved Management Choices
|
Scarisbrick, J.
|
|
|
211 |
S2 |
p.
|
artikel
|
| 61 |
A-276 Immunogenic Cell Death (ICD) and ICD-dependent Dendritic Cell Activation triggered by Extracorporeal Photopheresis in CTCL
|
Lackner, A.
|
|
|
211 |
S2 |
p.
|
artikel
|
| 62 |
A-292 Immunologic changes following chlormethine gel treatment in Cutaneous T-cell Lymphoma patients
|
Vetsika, E.-K.
|
|
|
211 |
S2 |
p.
|
artikel
|
| 63 |
A-227 Improved detection of molecular disease using a personalized cell-free DNA assay in patients with cutaneous T-cell lymphoma
|
Torres, A. Bastidas
|
|
|
211 |
S2 |
p.
|
artikel
|
| 64 |
A-205 Incidence patterns of primary cutaneous lymphoma in Greece: A 15-year study
|
Kaliampou, S.
|
|
|
211 |
S2 |
p.
|
artikel
|
| 65 |
A-238 Increased mortality due to lymphoma and infections in patients with mycosis fungoides and Sézary syndrome: A Swedish nationwide, population-based cohort study
|
Ivert, L.U.
|
|
|
211 |
S2 |
p.
|
artikel
|
| 66 |
A-274 Indolent primary cutaneous B-cell lymphomas resemble persistent antigen reactions without signs of dedifferentiation
|
Griss, J.
|
|
|
211 |
S2 |
p.
|
artikel
|
| 67 |
A-138 Indolent systemic mastocytosis: A severely symptomatic case - need for mast cell depleting therapy?
|
Altrichter, S.
|
|
|
211 |
S2 |
p.
|
artikel
|
| 68 |
A-168 International study of Sezary Syndrome reveals improved disease-specific survival from modern systemic therapies
|
Campbell, B.A.
|
|
|
211 |
S2 |
p.
|
artikel
|
| 69 |
A-248 Investigating Brentuximab Vedotin (BV) as a radiosensitizer in combination with low-dose TSEBT for Advanced CTCL: Clinical observations and experimental findings
|
Oymanns, M.
|
|
|
211 |
S2 |
p.
|
artikel
|
| 70 |
A-170 Is there microbial dysbiosis in CTCL? A pilot study
|
Peterknecht, E.
|
|
|
211 |
S2 |
p.
|
artikel
|
| 71 |
A-219 Italian expert opinion on the treatment of mycosis fungoides with chlormethine gel: results of a Delphi consensus
|
Violetti, S. Alberti
|
|
|
211 |
S2 |
p.
|
artikel
|
| 72 |
A-258 JAK2 rearrangements in indolent CD8+ cytotoxic mycosis fungoides
|
Rivera, M.
|
|
|
211 |
S2 |
p.
|
artikel
|
| 73 |
A-199 Keratinocytes Present Staphylococcus aureus Enterotoxins and Promote Malignant and Nonmalignant T Cell Proliferation in Cutaneous T-Cell Lymphoma
|
Zeng, Z.
|
|
|
211 |
S2 |
p.
|
artikel
|
| 74 |
A-124 Lacutamab in patients with relapsed and/or refractory mycosis fungoides: results from the TELLOMAK phase 2 trial
|
Porcu, P.
|
|
|
211 |
S2 |
p.
|
artikel
|
| 75 |
A-122 Lacutamab in Patients with Relapsed and Refractory Sézary Syndrome: Results from the TELLOMAK Phase 2 Trial
|
Bagot, M.
|
|
|
211 |
S2 |
p.
|
artikel
|
| 76 |
A-173 Long-Lasting Remission in a Patient with Sézary Syndrome Treated with Anecdotal Low Doses of Triple Therapy
|
Osmancevic, A.
|
|
|
211 |
S2 |
p.
|
artikel
|
| 77 |
A-299 Long-term management of advanced mycosis fungoides: Challenges in routine clinical practice
|
Hoellwerth, M.
|
|
|
211 |
S2 |
p.
|
artikel
|
| 78 |
A-285 MHC-I Upregulation Safeguards Neoplastic T Cells in the Skin Against NK Cell-mediated Eradication in Mycosis Fungoides
|
Chang, Y.-T.
|
|
|
211 |
S2 |
p.
|
artikel
|
| 79 |
A-250 Modes of metastasis: scRNAseq profiling of cutaneous T-cell lymphoma highlights CXCL13, TUSC3, and ANK1 in malignant T cells
|
Childs, B.
|
|
|
211 |
S2 |
p.
|
artikel
|
| 80 |
A-240 Mogamulizumab-Associated Rash in Patients with Mycosis Fungoides or Sezary Syndrome: A Real-World Analysis
|
Lohray, R.
|
|
|
211 |
S2 |
p.
|
artikel
|
| 81 |
A-272 Mogamulizumab-induced lymph node enlargement mimicking micosis fungoides progression
|
Falkenhain-Lopez, D.
|
|
|
211 |
S2 |
p.
|
artikel
|
| 82 |
A-200 Mogamulizumab in patients with mycosis fungoides or Sézary syndrome: Update on the German non-interventional MINT study
|
Assaf, C.
|
|
|
211 |
S2 |
p.
|
artikel
|
| 83 |
A-231 Mogamulizumab in Patients with Sézary Syndrome and Mycosis Fungoides Over 75 Years of Age: Real-World Data from 7 Italian Centers
|
Morsia, E.
|
|
|
211 |
S2 |
p.
|
artikel
|
| 84 |
A-186 Molecular Insights into Primary Cutaneous CD30+ T-cell Lymphoproliferative Disorders: Wnt/Beta-Catenin Pathway Activation and Prognostic Role of TP53 mutations?
|
Pirlog, R.
|
|
|
211 |
S2 |
p.
|
artikel
|
| 85 |
A-283 Multi-omics cytokine screening reveals immunosuppressive microenvironment in cutaneous T-cell lymphoma
|
Tsai, Y.-C.
|
|
|
211 |
S2 |
p.
|
artikel
|
| 86 |
A-140 Mycosis fungoides: Searching for biomarkers associated with early-stage progression
|
González, M. Rebollo
|
|
|
211 |
S2 |
p.
|
artikel
|
| 87 |
A-171 NanoString analysis of mycosis fungoides samples from patients included in EORTC 1652 clinical trial and treated with Atezolizumab
|
Rodríguez, M.
|
|
|
211 |
S2 |
p.
|
artikel
|
| 88 |
A-132 Navigating Modern Challenges in Early Mycosis Fungoides: A Case Report of a Peculiar Association and an Unusual Clinical Presentation
|
Struna, I.
|
|
|
211 |
S2 |
p.
|
artikel
|
| 89 |
A-178 Nb-UVB and PUVA Therapy for Early Mycosis Fungoides: A Cross-Sectional Study
|
Pileri, A.
|
|
|
211 |
S2 |
p.
|
artikel
|
| 90 |
A-218 New histopathologic patterns of Mogamulizumab-associated rash and a revision of already described histopathologic findings
|
Mitteldorf, C.
|
|
|
211 |
S2 |
p.
|
artikel
|
| 91 |
A-137 Oncogenic alterations in KIR3DL1 in cutaneous acral CD8+ lymphoproliferative disorder
|
Wobser, M.
|
|
|
211 |
S2 |
p.
|
artikel
|
| 92 |
A-232 Outcome of cutaneous T-cell lymphomas after allogeneic hematopoietic stem cell transplantation : focus on relapses and their management
|
Rosette, V.
|
|
|
211 |
S2 |
p.
|
artikel
|
| 93 |
A-230 Overlap: mycosis fungoides/Sezary syndrome and inflammatory dermatosis, a case series
|
Croci, G.A.
|
|
|
211 |
S2 |
p.
|
artikel
|
| 94 |
A-150 Paediatric onset lymphomatoid papulosis: results of a multicentre retrospective cohort study, on behalf of the EORTC Cutaneous Lymphoma Tumours Group (CLTG)
|
Blanchard, M.
|
|
|
211 |
S2 |
p.
|
artikel
|
| 95 |
A-282 Pagetoid reticulosis of the Ketron-Goodman type: a rare variant of Mycosis Fungoides
|
Bousmara, R.
|
|
|
211 |
S2 |
p.
|
artikel
|
| 96 |
A-201 Patient-reported symptoms and HRQL of MF and SS patients receiving mogamulizumab over 24 weeks: interim results from the PROSPER study
|
Scarisbrick, J.
|
|
|
211 |
S2 |
p.
|
artikel
|
| 97 |
A-182 Phase 2a Study of Topical 0.25% Hypericin in Mycosis Fungoides: Results and Review of the FLASH Study
|
Poligone, B.
|
|
|
211 |
S2 |
p.
|
artikel
|
| 98 |
A-180 Pluripotency Factor DPPA4 in Cell lines of T-Cell Lymphoma
|
Abu-Dawud, R.
|
|
|
211 |
S2 |
p.
|
artikel
|
| 99 |
A-237 Positron emission tomography/computed tomography guided choice of lymph node core biopsy. A useful tool
|
Mitsunaga, K.
|
|
|
211 |
S2 |
p.
|
artikel
|
| 100 |
A-154 Potential mogamulizumab-associated inflammatory bowel disease in cutaneous T-cell lymphoma management
|
Blanchard, G.
|
|
|
211 |
S2 |
p.
|
artikel
|
| 101 |
A-195 Preliminary Results from an Ongoing Phase 2, Open-Label, Multicenter, Single-Arm Study Assessing an Every-4-Week Dosing Schedule of Mogamulizumab in Patients with Cutaneous T-Cell Lymphoma
|
Scarisbrick, J.
|
|
|
211 |
S2 |
p.
|
artikel
|
| 102 |
A-194 Primary cutaneous anaplastic large cell lymphoma with locorregional lymph node involvement in a pregnant woman
|
Prieto-Torres, L.
|
|
|
211 |
S2 |
p.
|
artikel
|
| 103 |
A-185 Primary cutaneous follicule center lymphoma- differential diagnostic and prognostic aspects
|
Szepesi, A.
|
|
|
211 |
S2 |
p.
|
artikel
|
| 104 |
A-184 Primary cutaneous marginal zone Lymphoma or Lymphoproliferative disorder?Comparison of initial tumor, recurrence and outcome in 61 patients
|
Beltzung, F.
|
|
|
211 |
S2 |
p.
|
artikel
|
| 105 |
A-153 Primary cutaneous T-cell lymphoma not otherwise specified (NOS) uncovering a novel RAB27A variant in Griscelli syndrome type 2
|
Blanchard, G.
|
|
|
211 |
S2 |
p.
|
artikel
|
| 106 |
A-252 Prognosis about survival in primary cutaneous B cell lymphoma: a monocentric study of clinical characteristics of 98 patients
|
Cankaya, R.
|
|
|
211 |
S2 |
p.
|
artikel
|
| 107 |
A-117 Prognosis and management of Large Cell Transformation (LCT) in Mycosis Fungoides and Sézary Syndrome: LCT has poor outcome independent of clinical stage
|
Passby, L.
|
|
|
211 |
S2 |
p.
|
artikel
|
| 108 |
A-160 Pruritus and Quality of Life in Patients with Cutaneous T-cell Lymphoma
|
Roggo, A.
|
|
|
211 |
S2 |
p.
|
artikel
|
| 109 |
A-236 Quality of Life in Egyptian Mycosis Fungoides Patients Attending Cutaneous Lymphoma Clinic at Ain Shams University Hospitals: A Cross-Sectional Study
|
Zuelfakkar, N. M
|
|
|
211 |
S2 |
p.
|
artikel
|
| 110 |
A-295 Radiotherapy Dose for Primary Cutaneous Anaplastic Large Cell Lymphoma
|
Aykac, S.
|
|
|
211 |
S2 |
p.
|
artikel
|
| 111 |
A-120 Radiotherapy of Cutaneous Lymphomas: Real-world Pattern-of-Care Analysis Among EORTC Members
|
Elsayad, K.
|
|
|
211 |
S2 |
p.
|
artikel
|
| 112 |
A-121 Real-life evaluation of chlormethine gel in the treatment of stage IA-IVA2 mycosis fungoides: a single centre experience of 66 patients
|
Bakr, F.
|
|
|
211 |
S2 |
p.
|
artikel
|
| 113 |
A-198 Real-world effectiveness of mogamulizumab in Spain and Portugal: Second interim analysis of the MIBERIC study
|
Romero, P.O.
|
|
|
211 |
S2 |
p.
|
artikel
|
| 114 |
A-133 Real-world evidence study of brentuximab vedotin retreatment in patients with cutaneous T-cell lymphoma
|
Mitteldorf, C.
|
|
|
211 |
S2 |
p.
|
artikel
|
| 115 |
A-298 RESMAIN: Results of a multicenter, randomized, double blind, placebo-controlled trial to evaluate RESminostat for MAINtenance treatment in advanced stage Mycosis fungoides or Sézary syndrome
|
Stadler, R.
|
|
|
211 |
S2 |
p.
|
artikel
|
| 116 |
A-288 Retrospective Clinicopathological Comparative Study between Hypopigmented Mycosis Fungoides and Pityriasis Lichenoides Chronica
|
Ibrahim, M.
|
|
|
211 |
S2 |
p.
|
artikel
|
| 117 |
A-212 Retrospective Review of Mycosis Fungoides and Sézary Syndrome in Chinese Patients at a Hong Kong Tertiary Center
|
Wong, K.W.
|
|
|
211 |
S2 |
p.
|
artikel
|
| 118 |
A-151 Secondary Malignancy and Visceral Involvement in Cutaneous T-Cell Lymphoma: Diagnostic Differentiation
|
Pattisam, S.
|
|
|
211 |
S2 |
p.
|
artikel
|
| 119 |
A-107 Severe relapses of cutaneous T-cell lymphoma after treatment of chronic graft-versus-host disease with ruxolitinib
|
Cohen, E.
|
|
|
211 |
S2 |
p.
|
artikel
|
| 120 |
A-203 Sezary syndrome revealed by PD-L1 blockade for tumor stage mycosis fungoides
|
Delaleu, J.
|
|
|
211 |
S2 |
p.
|
artikel
|
| 121 |
A-263 Single-cell multiomics identifies formation of immunologic memory in CTCL - transition from blood to skin
|
Roggo, A.
|
|
|
211 |
S2 |
p.
|
artikel
|
| 122 |
A-269 Single-cell RNA sequencing of chronic idiopathic erythroderma compared to erythrodermic CTCL and atopic dermatitis defines disease-specific markers
|
Chennareddy, S.
|
|
|
211 |
S2 |
p.
|
artikel
|
| 123 |
A-265 Single cell sequencing delineates T-cell clonality and pathogenesis of the parapsoriasis disease group
|
Alkon, N.
|
|
|
211 |
S2 |
p.
|
artikel
|
| 124 |
A-267 Skin-Limited Versus Extended Manifestation In BPDCN Patients: A Retrospective Multi-Centre Observational Study
|
Iselin, C.
|
|
|
211 |
S2 |
p.
|
artikel
|
| 125 |
A-300 Skin microRNA profile of 12 cases of granulomatous slack skin - an extremely rare variant of mycosis fungoides
|
Cury-Martins, J.
|
|
|
211 |
S2 |
p.
|
artikel
|
| 126 |
A-257 Small Medium Pleomorphic T cell lymphoproliferative disorder - 20 years of experience from a specialist centre
|
Bashall, S.
|
|
|
211 |
S2 |
p.
|
artikel
|
| 127 |
A-287 Spatial atlas of noncommunicable inflammatory skin disease and cutaneous T cell lymphoma
|
Prompsy, P.
|
|
|
211 |
S2 |
p.
|
artikel
|
| 128 |
A-215 Spatial profiling of CD8+ T cells and lymphoma cells in mycosis fungoides patient skin
|
Nenonen, J.
|
|
|
211 |
S2 |
p.
|
artikel
|
| 129 |
A-145 Spatial transcriptomic and proteomic profiling of a B-cell rich tumor microenvironment in Mycosis fungoides
|
Nielsen, P.R.
|
|
|
211 |
S2 |
p.
|
artikel
|
| 130 |
A-255 Spontaneously regressive primary cutaneous diffuse large B-cell lymphoma, leg-type: a single-center retrospective study
|
Archimbaud, J.
|
|
|
211 |
S2 |
p.
|
artikel
|
| 131 |
A-220 Standardized flow cytometry for the detection and characterization of circulating CTCL cells: Update on a multicenter study
|
de Bie, F.J.
|
|
|
211 |
S2 |
p.
|
artikel
|
| 132 |
A-181 Staphylococcus aureus induces drug resistance in cancer T cells in Sézary syndrome
|
Vadivel, C.K.
|
|
|
211 |
S2 |
p.
|
artikel
|
| 133 |
A-111 Sub-analysis of the BELIEVE STUDY: Effectiveness and safety for retreatment with Brentuximab-vedotin in relapsed/refractory (R/R) Cutaneous T Cell Lymphoma (CTCL): a retrospective medical chart review study in Spain. NCT:04998331
|
Sureda-Balari, A.
|
|
|
211 |
S2 |
p.
|
artikel
|
| 134 |
A-251 Successful Treatment of Refractory Folliculotropic Mycosis Fungoides with Topical Ruxolitinib
|
Huen, A.O.
|
|
|
211 |
S2 |
p.
|
artikel
|
| 135 |
A-127 Sézary Syndrome in West Sweden: A Comprehensive Registry- Based Retrospective Analysis on PREHISTOPATHOLOGY, Clinical Features, and Treatment Patterns
|
Wojewoda, K.
|
|
|
211 |
S2 |
p.
|
artikel
|
| 136 |
A-247 Targeting metabolic requirements of malignant lymphocyte migration and disease dissemination
|
Schieke, S.
|
|
|
211 |
S2 |
p.
|
artikel
|
| 137 |
A-118 Targeting TGF-beta activation in cutaneous T-cell lymphomas
|
Giustiniani, J.
|
|
|
211 |
S2 |
p.
|
artikel
|
| 138 |
A-262 Targeting the hyperactive STAT3/5 Pathway in Cutaneous T-Cell Lymphoma: superior efficacy of multi-kinase inhibitor IQDMA over conventional PUVA therapy
|
Dey, S.
|
|
|
211 |
S2 |
p.
|
artikel
|
| 139 |
A-286 T cell receptor beta constant 1 as a potential marker for the assessment of T cell clonality in skin disease
|
Iselin, C.
|
|
|
211 |
S2 |
p.
|
artikel
|
| 140 |
A-259 TCR Vβ repertoire analysis and immunophenotyping to detect target molecules in patients with mycosis fungoides and Sézary syndrome
|
Schratter, H.
|
|
|
211 |
S2 |
p.
|
artikel
|
| 141 |
A-179 The Cutaneous Lymphoma International DIgital PAthology (CLIDIPA) Registry - a multi-center, collaborative initiative to facilitate Artificial Intelligence-driven research within Cutaneous Lymphomas
|
Schrader, A.
|
|
|
211 |
S2 |
p.
|
artikel
|
| 142 |
A-221 The effect of Anthracycline treatment on primary cutaneous T-cell lymphoma cells
|
de Bie, F.J.
|
|
|
211 |
S2 |
p.
|
artikel
|
| 143 |
A-225 The efficacy and safety of extracorporeal photopheresis (ECP) for treatment of mycosis fungoides and/or sézary syndrome in cutaneous T-cell lymphoma
|
Stone, V.
|
|
|
211 |
S2 |
p.
|
artikel
|
| 144 |
A-261 The impact of atopic dermatitis preceding cutaneous T-cell lymphoma and its effect on clinical outcomes: a retrospective review at a single tertiary referral center
|
Fleischli, A.
|
|
|
211 |
S2 |
p.
|
artikel
|
| 145 |
A-143 The role of OX-40 in tumor microenvironment of a Cutaneous T-cell Lymphoma (CTCL) in vivo chick embryo model
|
Karagianni, F.
|
|
|
211 |
S2 |
p.
|
artikel
|
| 146 |
A-270 Tinea in Cutaneous Lymphoma Patients
|
Szakonyi, J.A.
|
|
|
211 |
S2 |
p.
|
artikel
|
| 147 |
A-146 Topical hypericin ointment photodynamic therapy for early stage mycosis fungoides/CTCL - a Phase 2 real world investigator-initiated study
|
Kim, E.
|
|
|
211 |
S2 |
p.
|
artikel
|
| 148 |
A-175 Toward patient-tailored immunotherapy: targeting the TCR idiotype of clonal Sézary lymphomas
|
Herrero-Alonso, M.
|
|
|
211 |
S2 |
p.
|
artikel
|
| 149 |
A-207 Towards guidelines for clinical management of cutaneous lymphoproliferative disorders: an 2024 update
|
Willemze, R.
|
|
|
211 |
S2 |
p.
|
artikel
|
| 150 |
A-147 Transcriptomic and Genomic Profiling as Diagnostic and Prognostic Markers in CTCL Patients with a History of Atopic Dermatitis
|
Khoshniyati, S.
|
|
|
211 |
S2 |
p.
|
artikel
|
| 151 |
A-189 Treatment trends in advanced Mycosis fungoides and Sézary syndrome: an update from the PROCLIPI study
|
Roccuzzo, G.
|
|
|
211 |
S2 |
p.
|
artikel
|
| 152 |
A-244 Ultrasound-guided intralesional therapies in tumour-stage mycosis fungoides
|
Castro, J. Torre
|
|
|
211 |
S2 |
p.
|
artikel
|
| 153 |
A-235 Ultrasound patterns of cutaneous lymphomas
|
Monescillo, M. Recio
|
|
|
211 |
S2 |
p.
|
artikel
|
| 154 |
A-233 Update to the Cutaneous Lymphoma Application (CLApp v2.0) on iPhone. A resource tool for information and training for healthcare professionals
|
Sim, V.
|
|
|
211 |
S2 |
p.
|
artikel
|
| 155 |
A-106 Use of pegylated interferon-α2a in cutaneous T-cell lymphoma - a multicentre retrospective data analysis with 70 patients
|
Hansen, I.
|
|
|
211 |
S2 |
p.
|
artikel
|
| 156 |
Author Index
|
|
|
|
211 |
S2 |
p.
|
artikel
|
| 157 |
A-183 Utility of optical genome mapping in the study of Sézary syndrome
|
Parra-Navarro, L.
|
|
|
211 |
S2 |
p.
|
artikel
|
| 158 |
A-209 Utility of TCR-β and TCR-γ gene rearrangement to distinguish between tumour-stage mycosis fungoides and early-stage mycosis fungoides associated with CD30+ lymphoproliferative disorders
|
Castro, J. Torre
|
|
|
211 |
S2 |
p.
|
artikel
|
| 159 |
A-202 Validation Of Next Generation Sequencing Using EuroClonality-NDC Panel In Primary Cutaneous Lymphomas and comparison with Traditional PCR Techniques
|
Hatzakis, A.
|
|
|
211 |
S2 |
p.
|
artikel
|
| 160 |
A-284 VEXAS: a new clonal disease with specific diagnostic clues
|
Sarhan, M.
|
|
|
211 |
S2 |
p.
|
artikel
|
| 161 |
Contents
|
|
|
|
211 |
S2 |
p.
|
artikel
|
| 162 |
Copyright Page
|
|
|
|
211 |
S2 |
p.
|
artikel
|
| 163 |
Editorial Board
|
|
|
|
211 |
S2 |
p.
|
artikel
|
| 164 |
Peer Review Policy for the European Journal of Cancer (EJC)
|
|
|
|
211 |
S2 |
p.
|
artikel
|
| 165 |
Title Page
|
|
|
|
211 |
S2 |
p.
|
artikel
|
Tijdschrift beschrijving